Paczkowska Anna, Koligat Dorota, Nowakowska Elzbieta, Hoffmann Karolina, Bryl Wiesław
Acta Pol Pharm. 2014 Jan-Feb;71(1):197-203.
In adolescents, arterial hypertension (AH) is diagnosed much more frequently than previously thought--it affects 3.2% of the population aged 11-18. In Poland, at present, there are no cost analyses of treatment arterial hypertension among adolescents. The aim of the conducted studies was to analyze direct medical and non-medical costs in the time horizon of one calendar year (2010) of AH treatment in adolescents in Poland. A retrospective study from the societal perspective was based on data from 480 patients medical history cards obtained from the archives of the hospital. From this group, according to the criteria for inclusion in the study, a research group was selected consisting of 36 patients aged 16-18 years, with a diagnosed and treated hypertension. Analysis covered direct medical costs (costs of pharmacotherapy, doctors' visits and laboratory tests, hospitalization) and direct non-medical costs (cost of transport to the outpatient clinic). Average annual cost of hypertension treatment per patient was 89.96 Euro. The largest part of the structure of total costs related with hypertension treatment in adolescents in Poland were the costs of medical consultation with lab tests and diagnostic examinations--35.04% and pharmacotherapy costs--32.95%, with hospital stays rating somewhat lower with 19.12%, and the smallest part were the costs of the patient's transportation to the hypertension outpatient clinic--12.89%. Early identification of risk factors of such cardiovascular diseases as hypertension as early as in the developmental age, and their subsequent elimination, should be considered a good investment in the reduction of costs associated with hypertension treatment in adulthood.
在青少年中,动脉高血压(AH)的诊断频率比以前认为的要高得多——它影响11至18岁人口的3.2%。目前在波兰,尚无针对青少年动脉高血压治疗的成本分析。本研究的目的是分析波兰青少年在一个日历年(2010年)内AH治疗的直接医疗和非医疗成本。一项从社会角度进行的回顾性研究基于从医院档案中获取的480名患者病历卡的数据。从该组中,根据纳入研究的标准,选取了一个由36名16至18岁、被诊断并接受治疗的高血压患者组成的研究组。分析涵盖直接医疗成本(药物治疗、医生诊疗和实验室检查、住院费用)和直接非医疗成本(前往门诊的交通费用)。每位患者高血压治疗的年均成本为89.96欧元。在波兰青少年高血压治疗总成本结构中,最大的部分是实验室检查和诊断性检查的医疗咨询费用——35.04%,以及药物治疗费用——32.95%,住院费用略低,为19.12%,最小的部分是患者前往高血压门诊的交通费用——12.89%。早在发育年龄就尽早识别高血压等心血管疾病风险因素,并随后消除这些因素,应被视为降低成年期高血压治疗相关成本的一项良好投资。